# Marrow Therapeutics funding rounds and investors

As of 19 Nov 2026, Marrow Therapeutics has raised $173M across 1 verified round on record, plus 1 round still being checked; latest: $173 million Series A led by OrbiMed, Scion Life Sciences and 1 other, announced 17 Nov 2026.

An experimental treatment for sickle cell disease and beta thalassemia that aims to deliver genetic medicines directly to bone marrow cells.

Website: https://www.marrowtx.com/  
Headquarters: Watertown, Massachusetts  
Page: https://fireround.dev/companies/marrow-therapeutics

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-17 | Series A | $173 million | OrbiMed, Scion Life Sciences, venBio | Affinity Advisors, Columbia Threadneedle Investments, KKR, NEXTBio Capital, Opaleye, RTW Investments, Spruce Street Capital, Surveyor Capital (a Citadel company) | [marrowtx.com](https://www.marrowtx.com/news/marrow-therapeutics-launches-with-173-million-to-develop-genetic-medicines-for-bone-marrow-disorders), [businesswire.com](https://www.businesswire.com/news/home/20261117295792/en/Marrow-Therapeutics-Launches-With-%24173-Million-to-Develop-Genetic-Medicines-for-Bone-Marrow-Disorders), [axios.com](https://www.axios.com/pro/all-deals/2026/11/17/pro-rata-premium-first-look-ramon-space-traitomic-duetti) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.
